If you have been reading about metabolic research and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Last reviewed on 2026-08-01. Where a claim depends on a specific study, the study is described rather than over-claimed.
AOD-9604 is a synthetic peptide whose sequence matches the C-terminal fragment of human growth hormone, specifically residues 176 through 191. This region differs from the full hormone in its receptor interactions. The peptide is not a growth hormone secretagogue and does not bind the growth hormone receptor in the same manner. Researchers have examined it for effects on lipid metabolism, but its exact pharmacological profile remains an active area of study.
Development of AOD-9604 began in the 1990s as scientists sought to isolate metabolic effects of growth hormone without its growth-promoting actions. Early laboratory work focused on fat cells and animal models. Several human trials followed, examining changes in body composition and fat mass. Results have been mixed, and the peptide has not progressed to widespread clinical approval. Interest continues in research settings, particularly regarding its mechanism and potential metabolic targets.
Regulatory status varies by country. In the United States, AOD-9604 is not approved as a prescription drug. It is sometimes sold as a research chemical or dietary supplement, though such marketing may fall outside legal frameworks. The World Anti-Doping Agency prohibits its use in sport. Researchers must obtain it through legitimate suppliers and follow institutional rules. Its legal classification continues to evolve as authorities increasingly assess peptide products more broadly.
AOD-9604 is a synthetic peptide modeled on the C-terminal region of human growth hormone. It is often described as hGH fragment 176-191. Research interest arose because it was designed to isolate possible effects on fat metabolism from other actions of growth hormone. It is not a full growth hormone molecule. Its development history includes early laboratory and animal studies followed by human trials. The peptide has been examined in laboratory, animal, and limited human studies.
The compound has been studied as a potential treatment for obesity and related metabolic conditions. Published trials have examined changes in body weight, fat mass, and safety markers over limited durations. Results have been mixed or modest, and no large-scale outcome trials are established. Regulatory agencies in several countries have not approved it as a therapeutic drug. Some commercial products have been marketed outside regulated pharmaceutical channels, which raises questions about quality and claims.
In the scientific literature, AOD-9604 appears in reviews of growth hormone fragments and in discussions of peptide-based metabolic research. Some sources distinguish it from growth hormone itself, while others group it with compounds marketed for weight management. The evidence base is small compared with approved obesity medications. Questions about long-term efficacy and clinical relevance remain open, and independent replication of key findings is limited. Most published reports are early-stage and exploratory.
| Property | Value | Notes |
|---|---|---|
| Molecular class | Peptide fragment | Corresponds to hGH residues 176-191 |
| Common synonyms | AOD9604, hGH 176-191 | Also written as AOD-9604 |
| Typical form | Lyophilized powder | Often supplied in sealed vials |
| Solubility | Water-soluble | Dissolves in aqueous buffers |
| Regulatory status | Not approved as drug | Banned in sport; varies by country |
AOD-9604 drew attention in the 1990s and 2000s as a potential anti-obesity agent. Early work explored both injectable and oral routes, which is unusual for a peptide of this size. Animal studies reported changes in fat metabolism without the growth-promoting or insulin-like effects associated with full-length growth hormone. Subsequent human trials produced mixed or modest results, and the compound did not obtain regulatory approval for weight management in major markets. It remains known mainly through research literature, sports anti-doping listings, and non-approved supplement advertising.
AOD-9604 is prohibited in sport by the World Anti-Doping Agency under the peptide hormone class. Its presence in a sample can be detected through mass spectrometry-based methods, although the exact assay depends on the laboratory. In research settings, material is often supplied as a lyophilized powder for reconstitution. Buyers and researchers should note that products labeled AOD-9604 may vary in purity and actual peptide content. Analytical certificates and independent testing are common ways to verify identity, but no global harmonized standard exists for all commercial lots.
Research on AOD-9604 also examines how the peptide is measured in biological samples. Analytical methods may include liquid chromatography coupled with mass spectrometry, immunoassays, or both. Detection can be challenging because the peptide is small and may be present at low concentrations. Published methods vary in sensitivity and specificity, so comparative interpretation requires attention to validation details. The presence of related hGH fragments can complicate identification in some matrices.
AOD-9604 has been investigated mainly in the context of body fat and metabolic endpoints. Some early animal and small human studies reported changes in fat mass or lipid markers, but findings were not uniform. Larger, well-controlled trials that would establish efficacy are lacking in the public literature. As a result, claims about weight loss or metabolic benefit remain investigational rather than established. The distinction between a research finding and a proven clinical outcome is central to discussing this peptide.
Regulatory bodies have taken different approaches to AOD-9604. It is not approved as a prescription medicine by major agencies such as the U.S. Food and Drug Administration or the European Medicines Agency. In sport, the World Anti-Doping Agency prohibits peptide hormones, growth factors, and related substances, and AOD-9604 has been treated as a prohibited substance. These regulatory decisions reflect concerns about safety, efficacy, and potential misuse rather than proof of benefit.
When Stephen was captured in 1141 he was imprisoned in the castle, but when Robert was captured by Stephen's forces, Matilda was forced to exchange Stephen for Robert. Her son Henry, later to become Henry II of England, was kept safe in the castle, guarded and educated by his uncle Robert. The castle was later taken into royal hands, and Henry III spent lavishly on it, adding a barbican before the main west gate, a gate tower, and magnificent hall. The castle was also used to imprison Eleanor, Fair Maid of Brittany from 1224, under relatively comfortable conditions, almost to her death in 1241. The Earl of Gloucester had founded the Benedictine priory of St James in 1137. In 1140 St Augustine's Abbey was founded by Robert Fitzharding, a wealthy Bristolian who had loyally supported the Earl and Matilda in the war. As a reward for this support he would later be made Lord of Berkeley. The abbey was a monastery of Augustinian canons. In 1148 the abbey church was dedicated by the bishops of Exeter, Llandaff, and St. Asaph, and during Fitzharding's lifetime the abbey also built the chapter house and gatehouse. In 1172, following the subjugation of the Pale in Ireland, Henry II gave Bristolians the right to reside in and trade from Dublin. The medieval Jewish community of Bristol was one of the smaller communities in England. The Jews of Bristol were accused in a blood libel in 1183, but not many details are known. At the end of the 12th century, an archa was established in the city, without which Jews would not have been legally allowed to conduct business.
== Comparison to other indexes == METS-IR was compared with other non-insulin-based methods for estimating insulin sensitivity, including the Triglyceride-Glucose index (TyG), the triglyceride to HDL-C ratio, and the TyG-BMI index, showing a higher correlation and area under the ROC curve. However, in a study of Chinese subjects, Yu et al. found that TyG and TG/HDL-C performed better, likely due to ethnic differences in body composition. Given the role of ethnicity in modifying the performance of insulin sensitivity fasting-based indexes, further evaluations in different populations are required to establish performance of non-insulin-based methods.
== Active site structure == The multicopper active site of CP contains a type I (T1) mononuclear copper site and a trinuclear copper center distant by ca.12-13 Å. The tricopper center consists of two type III (T3) coppers and one type II (T2) copper ion. The two T3 copper ions are bridged by a hydroxide ligand while another hydroxide ligand links the T2 copper ion to the protein. The T1 center is bridged to the tricopper center by two histidine (His1020, His1022) residues and one Cys(1021) residue. The substrate binds near the T1 center and is oxidized by the T1 Cu2+ ion forming the reduced Cu+ oxidation state. The reduced T1 Cu+ then transfers the electron through the one Cys and two His bridging residues to the tricopper center. After four electrons have been transferred from the substrates to the copper centers, an O2 binds at the tricopper center and undergoes a four-electron reduction to form two molecules of water.
Sources: en.wikipedia.org
=== Reproductive system === In experiments with male rats, subchronic exposure to inhaled BaP has been shown to generally reduce the function of testicles and epididymis with lower sex steroid/testosterone production and sperm production.
Scarborough's drinking water is supplied by the R.C. Harris Filtration Plant at the foot of Victoria Park Avenue and the F. J. Horgan Filtration Plant. The F. J. Horgan Filtration Plant was built in 1979 and was formerly known as the 'Easterly Plant'. Upgrades completed in 2011 allow it to process up to 800 megalitres per day and it will also be the first plant to replace chlorine with ozone as its primary cleansing method. Wastewater for Scarborough is treated at the Highland Creek Treatment Plant. This plant was constructed in 1954 and started processing in 1956. It has undergone continual expansion to meet ongoing demand.
They selected a site where the Italian trenches were sheltered in a deep valley so that a gas cloud would persist. The following Battle of Caporetto broke the Italian lines, and the Central Powers overran much of northern Italy. That summer Hahn was accidentally poisoned by phosgene while testing a new model of gas mask. At the end of the war he was in the field in mufti on a secret mission to test a pot that heated and released a cloud of arsenicals.
== Physiological function == Until the late 1970s, hyaluronic acid was described as a "goo" molecule, a ubiquitous carbohydrate polymer that is part of the extracellular matrix. For example, hyaluronic acid is a major component of the synovial fluid and was found to increase the viscosity of the fluid. Along with lubricin, it is one of the fluid's main lubricating components. Hyaluronic acid is an important component of articular cartilage, where it is present as a coat around each cell (chondrocyte). When aggrecan monomers bind to hyaluronan in the presence of HAPLN1 (hyaluronic acid and proteoglycan link protein 1), large, highly negatively charged aggregates form. These aggregates imbibe water and are responsible for the resilience of cartilage (its resistance to compression). The molecular weight (size) of hyaluronan in cartilage decreases with age, but the amount increases. A lubricating role of hyaluronan in muscular connective tissues to enhance the sliding between adjacent tissue layers has been suggested. A particular type of fibroblasts, embedded in dense fascial tissues, has been proposed as being cells specialized for the biosynthesis of the hyaluronan-rich matrix. Their related activity could be involved in regulating the sliding ability between adjacent muscular connective tissues. Hyaluronic acid is also a major component of skin, where it is involved in repairing tissue. When skin is exposed to excessive UVB rays, it becomes inflamed (sunburn), and the cells in the dermis stop producing as much hyaluronan and increase the rate of its degradation.
Sources: en.wikipedia.org
AOD-9604 is a synthetic peptide fragment of human growth hormone, corresponding to amino acids 176-191. It is studied for potential effects on fat metabolism, but it is not approved as a drug in most countries. Its exact mechanism remains under investigation.
No, it is a small fragment of the full growth hormone protein. It does not appear to stimulate growth or increase growth hormone levels in the same way. Its actions are thought to be more limited to metabolic pathways.
Regulatory status varies. It is not approved for medical use in the United States or many other countries. It is banned in sport by WADA, and its sale as a supplement or research chemical may be subject to legal restrictions.
It is a synthetic peptide fragment derived from the C-terminal region of human growth hormone, commonly referred to as hGH fragment 176-191. It has been investigated for effects on fat metabolism, but it is not an approved medication in most jurisdictions.